Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Thermodynamic Properties for Hydrogen Liquefaction and Processing (ThermoPropHy)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Fundamental Constituents of Matter
Panel description: Particle, nuclear, plasma, atomic, molecular, gas, and optical physics
Countries involved: Germany
Call: ERC ADVANCED GRANTS (ERC-2021-ADG, 2021)
Start date: 2022-10-01
End date: 2027-09-30
Duration (months): 60.0
Total project cost (EUR): 2457146.0
EU funding (EUR): 2457146.0
Participants: 1
Project status: SIGNED

Hydrogen plays a prominent role in all concepts for CO2 mitigation; technologies for generation and for liquefaction of hydrogen need to be scaled up by orders of magnitude. This scale up has to rely on simulations of innovative processes, which are necessarily based on thermodynamic property models. An analysis of the available models indicates that properties of hydrogen are described with one order of magnitude larger uncertainty than properties of well-known fluids. Experience with process-simulation based scale-up shows that these uncertainties will likely result in large additional costs and delays. To improve the description of properties of hydrogen and to enable the application of advanced lique-faction concepts, fundamental breakthroughs are required with regard to the metrology of fluids at cryogenic temperatures and with regard to accurate modelling of these complex systems – ThermoPro-pHy addresses this pioneering scientific work. Experimental equipment will be developed that allows for highly accurate measurements of density and speed of sound at temperatures down to the triple point of hydrogen (14 K), far below current temperature limits. Property models will be developed that yield a highly accurate and consistent description of arbitrary mixtures of ortho- and parahydrogen for the first time, including the effects of the temperature dependent ortho/para-equilibrium. Solid phases of impurities affecting large-scale liquefaction processes will be described by models that are con-sistent to accurate fluid-phase models. Measurements and modelling of mixtures of helium, neon, and argon will establish an accurate basis for the application of mixed fluid cascade (MFC) processes for hydrogen liquefaction. ThermoPropHy will result not only in scientific breakthroughs with regard to the metrology of fluids and to accurate modelling of thermodynamic properties, but also in increased accuracy and credibility of process simulations for hydrogen technologies.

Keywords: hydrogen,hydrogen transport,hydrogen storage,hydrogen processing,thermodynamic properties,cryogenic mixtures
ECOlogical Deepwater Reverse Osmosis Plant (ECO DROP)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Norway
Call: EIC Accelerator 2025 - Short application (HORIZON-EIC-2025-ACCELERATOR-01, 2025)
Duration (months): 24.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

Currently, 3.6 billion people worldwide suffer have limied access to clean water, a basic necessity for life. Water scarcity severely impacts public health, social stability, and economic growth, pressuring governments to adopt sustainable and innovative solutions. Desalination offers a potential solution, but current technologies face critical challenges: high energy demands, costly water production, environmentally harmful brine discharge, and significant land usage. Flocean has developed Flocean Desal—an innovative, eco-friendly subsea desalination system installed on the seabed at optimal depths. Leveraging natural deep-ocean pressure for reverse osmosis, the system delivers freshwater while addressing key drawbacks of conventional plants. Flocean Desal reduces energy consumption by up to 50%, discharges "green concentrate" with a minimal salinity increase harmless to marine ecosystems, decreases land use by over 95%, and cuts the levelized cost of water (LCOW) in half. These features position Flocean Desal as a transformative solution for global water scarcity. This EIC project seeks to finalize the development of Flocean Desal and demonstrate a full-scale prototype, preparing the company , achieving TRL 9. The pilot aims to accelerate market deployment, ensuring Flocean’s first-mover advantage in the global desalination market.

Keywords: desalination,subsea,swro,sea water reverse osmosis,water treatment,deep sea,blue economy,sustainability,ocean,green discharge,environmental,energy efficiency,aquaculture
Freestanding energy-to-Hydrogen fuel by water splitting using Earth-abundant materials in a novel, eco-friendly, sustainable and scalable photoelectrochemical Cell system (FreeHydroCells)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Climate, Energy and Mobility
Theme: Energy
Destination: Sustainable, secure and competitive energy supply
Action type: Research and Innovation actions
Countries involved: Ireland,France,Germany,Italy
Call: Next generation of renewable energy technologies (HORIZON-CL5-2021-D3-03, 2021)
Start date: 2022-11-01
End date: 2026-02-28
Duration (months): 40.0
Total project cost (EUR): 3748300.25
EU funding (EUR): 3748300.0
Participants: 7
Project status: SIGNED

The FreeHydroCells project aims to create a new photoelectrochemical system capable of clean, efficient solar-to-chemical energy conversion, with hydrogen gas storing the chemical energy. The system would mimic the solar-energy absorption potential of a leaf by arraying cascades of nanometre thick semiconducting materials as buried pn-junctions that, when submerged in water and exposed to sunlight, are capable of freestanding photoelectrochemical water splitting. A number of technological challenges restrict the cost-effective efficiency of clean, green, solar-to-chemical hydrogen, state-of-the-art systems, making it commercially unattractive, and severely limiting hydrogen’s role in decarbonisation. However, the FreeHydroCells project proposes to leverage a number of advancements in thin film materials, devices, and processes to make similar breakthroughs in photoelectrochemical band-engineering for interconnected bands, defect minimisation, thin film thickness uniformity continuity to minimise drift-dominated transit times, carrier doping for high conductivity, carrier type selectivity and, importantly, preventing significant recombination of light-generated carriers by ensuring drift transport under multiple in-built electric fields. These breakthroughs would transform the transfer efficiency of solar-to-chemical energy via the carefully aligned redox potential and propel the photoelectrochemical water splitting reactions to morph solar energy into hydrogen bonds. The new materials system could be cost-effectively realised through modified delivery techniques of atomic layer deposition and chemical vapour deposition in manufacturing-compatible, large-area capable, equipment that is now common in commercial chip and solar cell processing technologies. FreeHydroCells’ multidisciplinary expertise is key to making this substantial science-to-technology leap: to verify a paradigm proof-of-concept for a self-driven system suitable for up-scaling and commercialisation.

Keywords: transition metal dichalcogenide,2d materials,alternative semiconductors,transparent conductive oxide,semiconducting oxides,renewable energy,hydrogen,photoelectrochemical cell,photoelectrolysis
Transforming The Skin Into a 3rd Kidney, Using a Non-Invasive, Renal Independent Drug Free system for the Treatment of Fluid Overload in Chronic Kidney Disease patients while being remotely monitored (AquaPass Ltd)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Israel
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 36.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

AquaPass Ltd. is a pioneering privately held medical device company based in Israel, focused on the development and manufacturing of a novel system intended for the removal of fluids in Chronic Kidney Disease and Cardiorenal Syndrome (chronic kidney disease + heart failure) patients suffering from fluid overload. Our cutting-edge system is non-invasive and drug-free, offering a revolutionary approach independent of renal function. Ideal for use in hospitals, clinics, and home settings, our device facilitates the removal of excess fluids directly from the interstitial compartment, where they accumulate, through the skin. The removed fluids are instantaneously evaporated into the air, ensuring a comfortable and controlled environment for the patient. With a high fluid removal rate comparable to a normally functioning kidney and effective as Intravenous Diuretics, our system targets an average of 250ml/hr, resulting in a meaningful fluid removal volume during a typical treatment session of 3-4 hours. Our technology was recognized as a breakthrough technology by the FDA and was tested in clinical trials which confirmed its safety and perfromance over current therapies. AquaPass is committed to transforming the treatment paradigm of fluid overload by developing an innovative approach for safer and more effective treatment for chronic kidney disease patients, allowing the caregivers and patients to remotely manage their condition at the convenience of the patient's home.

Keywords: renal failure,heart failure,dialysis,kidney failure,hospital at home,decongestion,fluid overload
Deformation Modelling of the Lithosphere in the Eastern Mediterranean-Anatolian Region (DEFMOD-LiMA)

Framework: Horizon Europe — Widening Participation and Strengthening the European Research Area
Programme: Widening participation and spreading excellence
Theme: Attracting and mobilising the best talents
Destination: Attracting and mobilising the best talents
Action type: Marie Skłodowska-Curie actions
Panel: Environment and Geosciences
Countries involved: Malta,Germany
Call: ERA Fellowships (HORIZON-WIDERA-2024-TALENTS-02, 2024)
Start date: 2026-03-02
End date: 2028-03-01
Duration (months): 24.0
Total project cost (EUR): 189474.24
EU funding (EUR): 189474.24
Participants: 4
Project status: SIGNED

The Eastern Mediterranean-Anatolian region presents a complex tectonic environment characterized by the interaction of the African, Arabian, and Eurasian plates. This area exhibits a unique interplay of subduction, continental collision, and backarc extension. The DEFMOD-LiMA project (Deformation Modelling of the Lithosphere in the Eastern Mediterranean-Anatolian Region) aims to elucidate mechanisms of lithospheric deformations in this intricate setting through a multidisciplinary approach that integrates geophysical and geodynamic methods. The project involves mapping high-resolution 3D isotropic, radially- and azimuthally anisotropic shear-wave velocity models of the crust and mantle, including detailed mapping of crustal and lithospheric thickness variations. The resulting models will be integrated with geological, geophysical, and geodetic observations to construct comprehensive 3D geodynamic models simulating the present-day lithospheric dynamics and their interplay with the underlying asthenosphere. This research is critical for quantifying lithospheric deformation and associated seismic hazards observed across the area and its active margins. DEFMOD-LiMA will contribute to improving seismic risk assessment in the area but also refining our knowledge of continental collisions in other regions of complex geodynamic evolution globally (e.g., Himalaya, the Appalachians in eastern North America, Tonga Fiji region in southwest Pacific Ocean). Accurate seismic risk assessment leads to well-defined strategies for earthquake risk reduction and emergency preparedness, supporting societies in developing and implementing sustainable development plans.

Keywords: seismology,surface wave tomography,receiver functions,gravity and geodynamic modelling,lithospheric deformation,seismic hazard,eastern mediterranean anatolian region
RESPILIQ - enteral CO2 absorption for the therapy of hypercapnic lung failure (RESPILIQ)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Germany
Call: EIC Accelerator Open 2023 (HORIZON-EIC-2023-ACCELERATOR-01, 2023)
Start date: 2024-05-01
End date: 2026-04-30
Duration (months): 24.0
Total project cost (EUR): 3603638.83
EU funding (EUR): 2499999.0
Participants: 1
Project status: SIGNED

Premature babies and patients with acute lung failure in the intensive care unit or COPD patients at home: they all suffer from the same potentially fatal condition: hypercapnia = an increased level of CO2 in the blood. In Europe alone there are around 1.8M people. Hypercapnia is one of the major challenges in the therapy of acute lung failure and long-term weaning in ICU and in the outpatient treatment of COPD, which has not yet been adequately solved. Our goal is to revolutionize therapy and significantly improve survival and, above all, the quality of life of these large patient groups suffering from hypercapnia. Instead of tackling the problem via the lungs, RESPILIQ uses the human gut as a respiratory organ. The intestine forms a highly effective exchange membrane for carbon dioxide (CO2). In the gut, RESPILIQ can bind CO2 from the intestinal fluid and excrete it via naturalis. Administered orally or rectally, RESPILIQ initiates a life-saving reduction of pCO2 in the blood

Keywords: hypercapnia,acute lung failure,copd
IMPROVED PREDICTABILITY OF EXTREMES OVER THE MEDITERRANEAN FROM SEASONAL TO DECADAL TIMESCALES (PREVENT)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Climate, Energy and Mobility
Theme: Climate
Destination: Climate sciences and responses for the transformation towards climate neutrality
Action type: Research and Innovation actions
Countries involved: Greece,Cyprus,Germany,France,Netherlands,Israel,Morocco
Call: Supporting the formulation of adaptation strategies through improved climate predictions in Europe and beyond (HORIZON-CL5-2022-D1-02, 2022)
Start date: 2023-10-01
End date: 2026-09-30
Duration (months): 36.0
Total project cost (EUR): 2997875.0
EU funding (EUR): 2997875.0
Participants: 8
Project status: SIGNED

It is well-established that the Mediterranean is a climate change hot spot that warms faster than the global mean rates and the frequency of extremes increases. Moreover, climate models often fail to provide sufficient skill in predicting extremes. Extremes are of utmost importance for many socio-economic sectors and activities, including human health, agriculture and water resource management, ecology, and tourism. Most of these activities are dominant drivers of the Mediterranean macro- and micro-economy. The overall objective of PREVENT is to improve the predictability of impact-relevant extremes in the Mediterranean region on timescales from seasonal to decadal using state-of-the-art dynamical, statistical, and machine learning methods. Additionally, PREVENT brings together experts in different disciplines and geographical regions for a comprehensive study of impact-relevant climate extremes in the Mediterranean with the goal to improve their seasonal and decadal predictions in a changing climate. PREVENT intent to 1. Define for local climate extreme hotspot regions, including major urban centers in the Mediterranean. 2. Provide new management tools that can be used in many domains, to guide and direct processes, support monitoring activities, and increase organizational efficiency 3. Develop awareness and competencies by enabling policymakers, industry, farmers, and other producers to understand, promote and practice the inclusion of seasonal and decadal data in their project management. PREVENT has a small flexible consortium consisting of colleagues with great experience in the Mediterranean climate and especially the analysis of extreme climate events and the use of impact models. One of the main PREVENT ambitions is to enhance gender balance in the coordination of EU- funded research programs and give young researchers the opportunity to participate as leaders in the work packages by providing fresh new ideas for research.

Keywords: extremes,mediterranean,seasonal forecast,decadal prediction,impact model
Understanding and improving choices: investigating the role of stress-related neuromodulators and psychiatric diagnoses in decision-making and precommitment (BETTERCHOICES)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Germany
Call: MSCA Postdoctoral Fellowships 2022 (HORIZON-MSCA-2022-PF-01, 2022)
Start date: 2024-01-01
End date: 2026-06-30
Duration (months): 30.0
Total project cost (EUR): 217309.2
EU funding (EUR): 217309.2
Participants: 2
Project status: TERMINATED

Everyday decisions, such as deciding what to eat or whether to exercise, have a profound effect on our long-term health. Both stress and a diagnosis of certain psychiatric disorders are two factors which can impact these decisions often resulting in detrimental health outcomes. BETTERCHOICES will investigate the biological mechanisms of this altered decision making and test the effectiveness of a behavioural strategy which aims to improve decision making. In STUDY 1, I will investigate how pharmacological increases in two key stress related neuromodulators - cortisol and noradrenaline - affect participant's willingness to exert effort to obtain rewards (RO1). Additionally, I will test whether precommitment can buffer the detrimental effects of increases in cortisol and noradrenaline action on effort-based decisions (RO2). Precommitment involves pre-emptively restricting one’s future choice set to improve decision making, yet we do not know how or if people use this strategy under stress or in psychiatric disorders. In STUDY 2, I will develop a novel task, the precommit-to-eat paradigm, to precisely quantify the individual effectiveness of precommitment when participants make food choices (RO3). This paradigm will then be used to test the effectiveness of precommitment in patients with a diagnosis of depression or schizophrenia during a non-academic placement in a psychiatric clinic. During the non-academic placement, I will also implement a psychoeducation program to help patients make better health decisions using behavioural strategies, such as precommitment. By using an interdisciplinary approach and combining methodologies from psychopharmacology and behavioural economics, BETTERCHOICES will provide novel insights into how we make decisions under stress. The project will also help to improve everyday decision making both in healthy participants and in psychiatric disorders thereby promoting better health outcomes.

Keywords: decision making precommitment noradrenaline hydrocortisone acute stress psychopharmacology effort discounting food choices depression schizophrenia
RNA-based cancer ImmunotheraPeutics to Enhance CROssPrimming (RIPECROP)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Immunity, Infection and I mmunotherapy
Panel description: The immune system , related disorders  and their mechanisms , biology of infectious agents and infection, biological basis of prevention and treatment of infectious diseases , innovative imm unological tools and approaches , including  therapies
Countries involved: Spain
Call: ERC ADVANCED GRANTS (ERC-2023-ADG, 2023)
Start date: 2024-10-01
End date: 2029-09-30
Duration (months): 60.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 2
Project status: SIGNED

Cancer immunotherapy achieves unprecedented efficacy against a number of malignant diseases. Preclinical experiments in mouse models conclude that type-1 dendritic cells (cDC1) that present tumor antigens are an absolute requirement for most immunotherapy strategies to be efficacious, including those routinely applied to cancer patients at present. cDC1 cells are specialized in redirecting engulfed cell-associated antigens to the class I MHC antigen-presentation pathway in the context of IL-12 production and co-stimulation, at least when cDC1 cells are in the presence of moieties denoting viral infection. Such phenomena are key to prime anti-tumor T lymphocytes through a mechanism known as crosspriming. The RIPECROP project will test immunotherapy agents that enhance the numbers and performance of cDC1 in the tumor tissue microenvironment. The strategies will be based on mRNA constructs that will encode engineered forms of the cDC1 growth factor sFLT-3L, single-chain interleukin-12, cDC1 specific chemoattractants and bispecific costimulatory ligands targeted to surface proteins of cDC1 cells. The new therapeutic agents in the form of coding mRNAs will be expressed in vivo either intratumorally or using the mRNA-transferred liver as an internal “biofactory” to systemically produce the encoded proteins and their combinations. Innovative in-vivo screenings based on hydrodynamic gene transfer of the liver with various expression plasmids encoding heterodimerization systems will be performed to identify suitable new mRNA-based immunotherapeutic chimeric constructs to enhance antitumor T-cell crosspriming. Overall, a novel mRNA-based toolbox will be studied both in terms of anti-tumor efficacy and regarding the mechanisms of action, in such a manner, that crosspriming will become exploitable in combinatorial approaches for cancer immunotherapy.

Keywords: crosspriming,cancer immunotherapy,mrna,intratumoral,adoptive t cell therapy,viral mimetics,radiotherapy,synergistic immunotherapy combinations